• Vaccine Name: RBD-rAAV-SARS-CoV-version-02
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Vaccine Ontology ID: VO_0004679
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Vector:
  • Vector name:
  • VO vector ID: VO_0000571
• Preparation: RBD-rAAV prime/RBD-specific T cell peptide boost (Du et al., 2008).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: Balb/c (Du et al., 2008)
• Host age: 4-6 weeks (Du et al., 2008)
• Host gender: Female (Du et al., 2008)
• Vaccination Protocol: Mice were separated into 4 groups (9 mice per group) and primed with RBD-rAAV [intramuscular (i.m.), 2 × 10^11 VP /200 μl)] or RBD-peptides (N50 and N60, 50 μg each) plus CpG ODN (25 μg) [subcutaneous, (s.c.)] or blank AAV, and boosted with RBD-rAAV or RBD-Pep or AAV, respectively (Du et al., 2008).
• Vaccine Immune Response Type: VO_0003057
• Immune Response: Induced high level of IgG Ab response, reaching a peak 3 months post-vaccination, plateaued for 3 months, then decreased. Mucosal IgA Ab peaked 1 month after vaccination, then decreased in the next 5 months. Vaccination induced high levels of Agspecific IL-2+ T cells but slightly lower levels of IFN-γ+ T cells in the spleen. Single dose did not trigger significant IL-2+ and IFN-γ+ T cell response. (Du et al., 2008)
• Challenge Protocol: Forty days post-vaccination, mice were anaesthetized with isoflurane and i.n. inoculated with 50 μl of SARS-CoV strain GZ50 (5 × 10^5 TCID50) (Du et al., 2008).
• Efficacy: Compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide (RBD-Pep) boost induced similar levels of Th1 and neutralizing antibody responses that protected the vaccinated mice from subsequent SARS-CoV challenge, but stronger Th2 and CTL responses. No significant immune responses and protective effects were detected in mice vaccinated with RBD-Pep or blank AAV alone (Du et al., 2008).